12:00 AM
 | 
Apr 29, 2002
 |  BioCentury  |  Product Development

Delaying gratification with Erbitux

Merck KGaA's decision to delay submission of an MAA for Erbitux cetuximab may end up getting it to market almost as fast and with a broader indication, due to quirks in the European regulatory system.

After a recent meeting to assess the progress of a European Phase II trial of cetuximab in colorectal cancer, Merck (FSE:MRK, Darmstadt, Germany) decided to postpone what was to have been a late 2002 European filing for head and neck cancer. Instead, the company now will seek simultaneous approval of...

Read the full 408 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >